Discussion on "inflammation-cancer" transformation and prevention and treatment of TCM of reflux esophagitis based on the theory of Yin-fire
-
摘要: 反流性食管炎(reflux esophagitis，RE)是一种由胃内容物反流导致的慢性持续性食管炎症疾病。该病全球发病率呈不断上升趋势，现已被证实与食管癌(esophageal cancer，EC)的发生密切相关。长期存在的RE易诱发EC，严重威胁人类身心健康。“炎-癌”转化是炎症性疾病发展为癌症的转归动态总称，高度重视RE“炎-癌”转化对防治EC意义重大。本文基于李东垣的阴火理论，认为阴火产生的根本原因在于脾胃虚弱、元气不足。元气不足则阴火上乘，日久则成癌瘤，这是RE“炎-癌”转化的关键。本文从阴火理论出发，探讨RE“炎-癌”转化及其中医药防治思路，强调必须全面把握该病的动态变化，并针对其不同病理阶段进行辨证论治。主张以充养元气、清泻阴火、解毒祛邪治之，从而断阴火之源、折阴火之势和消阴火之积，最终延缓、阻断甚至逆转RE“炎-癌”转化过程，最大化发挥中医药的疗效。Abstract: Reflux esophagitis(RE) is a chronic persistent esophageal inflammatory disease caused by reflux of gastric contents. The global incidence of the disease is on the rise, and it has been confirmed to be closely related to the occurrence of esophageal cancer(EC). Long-standing RE is easy to induce EC, which seriously threatens human physical and mental health. "Inflammation-cancer" transformation is a general term for the development of inflammatory diseases into cancer. It is of great significance to attach great importance to and intervene in "inflammation-cancer" transformation for the prevention and treatment of EC. Based on theory of LI Dongyuan of Yin-fire, this paper holds that the root cause of Yin-fire lies in the weakness of spleen and stomach and the lack of vitality. The lack of vitality is superior to Yin-fire, and over time, it becomes a cancer tumor, which is the key of RE "inflammation-cancer" transformation. Based on the theory of Yin-fire, this paper discusses RE "inflammation-cancer" transformation and its prevention and treatment ideas of Chinese medicine, emphasizing that the dynamic changes of the disease must be fully grasped, and syndrome differentiation and treatment should be carried out for different pathological stages. It is advocated to treat RE by nourishing primordial Qi, clearing and purging Yin-fire, detoxifying and dispelling evil, so as to break the source of Yin-fire, fold the potential of Yin-fire and eliminate the accumulation of Yin-fire, and finally delay, block or even reverse the process of RE "inflammation-cancer" transformation, so as to maximize the efficacy of Chinese medicine.
-
-
[1] Davis TA, Gyawali CP. Refractory Gastroesophageal Reflux Disease: Diagnosis and Management[J]. J Neurogastroenterol Motil, 2024, 30(1): 17-28. doi: 10.5056/jnm23145
[2] Vergouwe FW, Gottrand M, Wijnhoven BP, et al. Four cancer cases after esophageal atresia repair: Time to start screening the upper gastrointestinal tract[J]. WJG, 2018, 24(9): 1056-1062. doi: 10.3748/wjg.v24.i9.1056
[3] Habu Y, Hamasaki R, Maruo M, et al. Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan[J]. J Gen Fam Med, 2021, 22(5): 237-245. doi: 10.1002/jgf2.429
[4] Liu CQ, Ma YL, Qin Q, et al. Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040[J]. Thorac Cancer, 2023, 14(1): 3-11. doi: 10.1111/1759-7714.14745
[5] 彭孟凡, 田硕, 李晨辉, 等. 食管癌发病机制及中医药临床干预研究进展[J]. 中国实验方剂学杂志, 2022, 28(12): 267-274.
[6] Singh N, Baby D, Rajguru JP, et al. Inflammation and cancer[J]. Ann Afr Med, 2019, 18(3): 121-126. doi: 10.4103/aam.aam_56_18
[7] Sone JH, Han YM, Kim WH, et al. Oxidative stress from reflux esophagitis to esophageal cancer: the alleviation with antioxidants[J]. Free Radic Res, 2016, 50(10): 1071-1079. doi: 10.1080/10715762.2016.1181262
[8] Cui SJ, Li Y, Zhou RM, et al. TIM-3 polymorphism is involved in the progression of esophageal squamous cell carcinoma by regulating gene expression[J]. Environ Mol Mutagen, 2021, 62(4): 273-283. doi: 10.1002/em.22432
[9] Booka E, Tsubosa Y, Yokota T, et al. Whole exome sequencing and deep sequencing of esophageal squamous cell carcinoma and adenocarcinoma in Japanese patients using the Japanese version of the Genome Atlas, JCGA[J]. Esophagus, 2021, 18(4): 743-752. doi: 10.1007/s10388-021-00835-z
[10] Kavanagh ME, O'Sullivan KE, O'Hanlon C, et al. The esophagitis to adenocarcinoma sequence; the role of inflammation[J]. Cancer Lett, 2014, 345(2): 182-189. doi: 10.1016/j.canlet.2013.08.017
[11] Souza RF. Reflux esophagitis and its role in the pathogenesis of Barrett's metaplasia[J]. J Gastroenterol, 2017, 52(7): 767-776. doi: 10.1007/s00535-017-1342-1
[12] O'Sullivan KE, Phelan JJ, O'Hanlon C, et al. The role of inflammation in cancer of the esophagus[J]. Expert Rev Gastroent, 2014, 8(7): 749-760. doi: 10.1586/17474124.2014.913478
[13] 张北华, 周秉舵, 唐旭东. 胃食管反流病中医诊疗专家共识(2023)[J]. 中医杂志, 2023, 64(18): 1935-1944.
[14] 叶斌, 叶蔚. 中医升降理论在反流性食管炎及其并发症中的应用[J]. 中国中医基础医学杂志, 2012, 18(3): 292-293.
[15] 王笠筑, 王捷虹. 沈舒文"以润为降"治食管癌咽食困难经验撷萃[J]. 中华中医药杂志, 2024, 39(2): 796-799.
[16] 陈玉龙, 张瑞, 郑玉玲. 食管癌辨治学术思想及经验撷英[J]. 中华中医药杂志, 2022, 37(2): 835-838.
[17] 郭程程, 焦华琛, 李运伦. 李东垣阴火本质探究[J]. 中华中医药杂志, 2021, 36(7): 3874-3876.
[18] 刘礼剑, 谢胜, 黄晓燕, 等. 从虚火论治胃食管反流病[J]. 江西中医药, 2019, 50(6): 18-20.
[19] 王加锋, 展照双. 阴火论探微及临证应用[J]. 山东中医杂志, 2016, 35(3): 193-195.
[20] 崔翰博, 关怿, 魏青, 等. 结合临证再探"阴火"[J]. 中国中医基础医学杂志, 2020, 26(12): 1763-1764, 1822.
[21] 谢胜, 张越, 周晓玲. 以背俞调节脾胃功能的"以俞调枢"理论的提出与构建[J]. 辽宁中医杂志, 2011, 38(9): 1876-1877.
[22] 袁创基. 李东垣"火与元气不两立"理论及临床应用研究[D]. 广州: 广州中医药大学, 2021.
[23] 彭孟凡, 李鸣, 苗晋鑫, 等. 基于"炎-癌转化"探讨炎症对肿瘤的影响及中医药干预作用[J]. 中国实验方剂学杂志, 2022, 28(22): 196-204.
[24] 罗贞艺, 谭金晶, 张羽, 等. 基于"阴火-线粒体氧化应激"相关性论治胃食管反流病[J]. 辽宁中医药大学学报, 2023, 25(12): 111-115.
[25] 王培屹, 李菁, 李跃军. "以脾为本, 五脏相关"的李东垣"阴火理论"[J]. 辽宁中医杂志, 2021, 48(4): 74-77.
[26] 王欣妍, 周彤, 李经蕾, 等. 从"阴火"理论探讨恶性肿瘤化疗耐药的形成及防治策略[J]. 中医杂志, 2023, 64(20): 2082-2085.
[27] 黄文博, 潘丽, 黄娅, 等. 基于能量代谢重编程论"阴火"与中医肿瘤发生学[J]. 中医杂志, 2022, 63(10): 905-909.
[28] 廖冬颖, 刘家宇, 王洪武, 等. 基于"寒-浊-阴火"辨治恶性肿瘤[J]. 江苏中医药, 2023, 55(9): 39-42.
[29] 罗贞艺, 张羽, 蒙华莹, 等. 基于"以枢调枢"与ICC线粒体自噬相关性探讨芪石升降归元饮治疗GERD的理论基础[J]. 世界科学技术-中医药现代化, 2023, 25(9): 2989-2995.
[30] 罗贞艺, 黄美祯, 蒙华莹, 等. 基于"以枢调枢"探讨芪石升降归元饮对胃食管反流病大鼠细胞自噬的影响[J]. 时珍国医国药, 2023, 34(5): 1059-1063.
[31] 王立春, 王定国, 黄土超, 等. 国医大师林天东治疗反流性食管炎经验[J]. 时珍国医国药, 2023, 34(8): 1990-1991.
[32] 周滔, 陈瑞琳, 牛柯敏, 等. 危北海教授从"虚、气、火、瘀"病因辨治胃食管反流病的临床经验[J]. 中国中西医结合消化杂志, 2018, 26(9): 788-790. https://zxyxh.whuhzzs.com/article/doi/10.3969/j.issn.1671-038X.2018.09.17
[33] 蔡可珍, 郑琴, 魏韶锋, 等. 四君子汤的研究进展及质量标志物预测[J]. 中华中医药学刊, 2023, 41(11): 161-168.
[34] 杨洁, 陈文剑. 四君子汤合四逆散联合埃索美拉唑治疗反流性食管炎的疗效观察[J]. 时珍国医国药, 2009, 20(7): 1794-1795.
[35] Xu Y, Surman DR, Diggs L, et al. Bile acid-induced "Minority MOMP" promotes esophageal carcinogenesis while maintaining apoptotic resistance via Mcl-1[J]. Oncogene, 2020, 39(4): 877-890. doi: 10.1038/s41388-019-1029-6
[36] 陈萌, 凌江红, 魏珏, 等. 基于阴火理论探讨慢性胰腺炎"炎-癌转化"与防治策略[J]. 上海中医药杂志, 2023, 57(6): 12-15.
[37] 陈健萍, 余长晖, 翁映虹, 等. 论泻黄散与补脾胃泻阴火升阳汤治疗脾胃郁火的异同[J]. 四川中医, 2021, 39(1): 17-19.
[38] 李强, 郭蕾, 陈少丽, 等. 补中益气汤治疗胃肠病的实验研究进展[J]. 中成药, 2016, 38(6): 1360-1363.
[39] 杨海卿, 王科峰, 郭伟. 加味补中益气汤联合奥美拉唑肠溶胶囊治疗老年反流性食管炎的疗效及对生活质量和复发情况的影响[J]. 中国老年学杂志, 2017, 37(22): 5642-5644.
[40] 雷丹丹, 张静文, 李梦阁, 等. 从"火证病机"角度探讨胃食管反流病临证发微[J]. 四川中医, 2023, 41(7): 22-26.
[41] 李鹏, 王拥军, 陈光勇, 等. 中国巴雷特食管及其早期腺癌筛查与诊治共识(2017万宁)[J]. 中国实用内科杂志, 2017, 37(9): 798-809.
[42] 周曌莹, 单葳葳, 房子铭, 等. 谢晶日教授运用药对治疗巴雷特食管经验[J]. 世界中医药, 2023, 18(12): 1715-1718.
[43] 吴东南, 范世平, 肖政, 等. 饶振芳运用半夏泻心汤加味治疗Barrett食管经验[J]. 湖北中医杂志, 2016, 38(6): 25-26.
[44] 李志鹏, 李伟兵, 包玉花. 顾奎兴教授辨治食管癌经验[J]. 南京中医药大学学报, 2020, 36(6): 892-894.
-
计量
- 文章访问数: 181
- 施引文献: 0
下载: